日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors

一项针对晚期或转移性实体瘤患者的溶瘤病毒ASP9801的1期开放标签研究

Villano, John L; Luke, Jason J; Julian, Ricklie; Fountzilas, Christos; Patel, Manish R; Chisamore, Michael J; Bhattacharya, Pranob; Takeshita, Shigeru; Soukharev, Serguei; Yamada, Shunsuke; Zhang, Leshi; Wentzel, Kristopher P

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study

Pirtobrutinib,一种高选择性、非共价(可逆)BTKi,用于治疗复发/难治性边缘区淋巴瘤:BRUIN 1/2期研究

Patel, Krish; Vose, Julie M; Nasta, Sunita D; Brown, Jennifer R; Maddocks, Kami J; Woyach, Jennifer A; Shah, Nirav N; Fakhri, Bita; Tessoulin, Benoit; Ma, Shuo; Jagadeesh, Deepa; Lech-Maranda, Ewa; Coombs, Catherine C; Patel, Manish R; Rhodes, Joanna M; Ujjani, Chaitra; Hoffmann, Marc S; Cheah, Chan Y; Munir, Talha; Lewis, David; Scarfò, Lydia; Eyre, Toby A; Alencar, Alvaro; Cohen, Jonathon B; Zelenetz, Andrew D; Tsai, Donald E; Li, Mei; Bian, Yuanyuan; Abada, Paolo; Balbas, Minna; Zinzani, Pier Luigi

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Divarasib 单药治疗 KRAS G12C 阳性非小细胞肺癌患者:一项 I 期研究的长期随访

Sacher, Adrian G; Miller, Wilson H Jr; Patel, Manish R; Paz-Ares, Luis; Santoro, Armando; Ahn, Myung-Ju; Dziadziuszko, Rafal; Freres, Pierre; Luo, Jia; Bowyer, Samantha; Desai, Jayesh; Markman, Ben; De Miguel, Maria; Deva, Sanjeev; Falcon, Alejandro; Alonso, Guzman; Guedes, João Daniel; Kim, Se Hyun; Krebs, Matthew G; Laurie, Scott A; Massarelli, Erminia; Medina, Laura; Prenen, Hans; Amatu, Alessio; Van Dongen, Marloes; Choi, Yoonha; Hou, Xuefeng; Qi, Ting; Lin, Mark T; Koli, Kalpesh; Mayo, Mariah C; Yau, Kenneth K; Royer-Joo, Stephanie; Chang, Julie; Jun, Tomi; Dharia, Neekesh V; Schutzman, Jennifer L; Lorusso, Patricia

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

一项针对对标准疗法无效的不可切除的局部晚期或转移性实体瘤患者的sacituzumab tirumotecan 1/2期研究结果

Ouyang, Quchang; Rodon, Jordi; Liang, Yan; Wu, Xinhong; Li, Qun; Song, Lihua; Yan, Min; Tong, Zhongsheng; Liu, YunPeng; Wainberg, Zev A; Wang, Ying; Geng, Cuizhi; Ulahannan, Susanna V; Yu, Guohua; Sharma, Manish R; Wang, Xiang; Wang, Judy S; Spira, Alexander; Zhao, Weihong; Sanborn, Rachel E; Cheng, Ying; Wang, Xian; Liu, Gesha; Li, Yaling; Ge, Junyou; Chartash, Elliot; Akala, Omobolaji O; Yin, Yongmei

TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8(+) T-cell subsets in lymph nodes and tumors

TGF-βRII/IL-15免疫治疗复合物靶向淋巴结和肿瘤中耗竭的CD8(+) T细胞亚群

George, Varghese K; Wong, Hing C; Felices, Martin; Rubinstein, Mark P; Shrestha, Niraj; Valderrama, Natalia; Farzaneh, Hamidreza; Kong, Lin; Gilkes, Crystal; Thompson, Alyssa; Larson, Megan; Liu, Bai; Zhu, Xiaoyun; Leclerc, Gilles Michel; Chung, Dongjun; Xie, Juan; Krull, Jordan; Gomez, Lucas; Kanakaraj, Leah; Bialik, Ann; Egan, Jack O; You, Lijing; Liu, Xianglan; Teodorescu, Rachael; Gutierrez, Ana K Karen; Echeverri, Christian; Rodriguez, Reynier; Wang, Zheng; Xing, Jilan; Gonzalez, Neicy; Chaturvedi, Pallavi; Patel, Manish R; Wangen, Rose; Cao, Qing; Rhode, Peter R; Miller, Jeffrey S; Geller, Melissa A

Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1

卡美司群联合三种全球获批的 CDK4/6 抑制剂治疗 ER+、HER2- 晚期乳腺癌女性患者:SERENA-1 研究结果

Baird, Richard D; Bermejo de Las Heras, Begoña; Ruiz-Borrego, Manuel; Vaklavas, Christos; Moreno, Irene; Oliveira, Mafalda; Armstrong, Anne; Turner, Nicholas; Incorvati, Jason; Twelves, Chris; Ciruelos, Eva; Hamilton, Erika; Patel, Manish R; Kabos, Peter; Ciardullo, Carmela; Klinowska, Teresa; Lindemann, Justin P O; Mathewson, Alastair M; Morrow, Christopher J; Sykes, Andy; Yang, Jincheng; Zhang, Bairu; Victoria, Ivan

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

在对布鲁顿酪氨酸激酶抑制剂不耐受的B细胞恶性肿瘤患者中,吡托布鲁替尼单药治疗:I/II期BRUIN试验结果

Shah, Nirav N; Wang, Michael; Roeker, Lindsey E; Patel, Krish; Woyach, Jennifer A; Wierda, William G; Ujjani, Chaitra S; Eyre, Toby A; Zinzani, Pier Luigi; Alencar, Alvaro J; Ghia, Paolo; Lamanna, Nicole; Hoffmann, Marc S; Patel, Manish R; Flinn, Ian; Gerson, James N; Ma, Shuo; Coombs, Catherine C; Cheah, Chan Y; Lech-Maranda, Ewa; Fakhri, Bita; Kim, Won Seog; Barve, Minal A; Cohen, Jonathon B; Jurczak, Wojciech; Munir, Talha; Thompson, Meghan C; Tsai, Donald E; Bao, Katherine; Cangemi, Nicholas A; Kherani, Jennifer F; Walgren, Richard A; Han, Hongmei; Ruppert, Amy S; Brown, Jennifer R

Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results

帕拉塞群(Palazestrant)是一种新型口服完全雌激素受体拮抗剂(CERAN)和选择性雌激素受体降解剂(SERD),用于治疗ER+/HER2-晚期或转移性乳腺癌患者:1/2期研究结果

Hamilton, Erika P; Patel, Manish R; Borges, Virginia F; Meisel, Jane L; Okera, Meena; Alemany, Carlos A; Pluard, Timothy J; Wesolowski, Robert; Sabanathan, Dhanusha; Miller, Kathy D; Conlin, Alison K; McCarthy, Nicole; Shaw, Morena; Tonda, Margaret; Shilkrut, Mark; Lin, Nancy U

Ultra-Processed Food and Chronic Kidney Disease Risk: A Systematic Review, Meta-Analysis, and Recommendations

超加工食品与慢性肾脏病风险:系统评价、荟萃分析及建议

Leonberg, Kristin E; Maski, Manish R; Scott, Tammy M; Naumova, Elena N

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors

一项开放标签、多中心、I期研究,旨在评估Adavosertib联合Durvalumab治疗晚期实体瘤患者的安全性和耐受性

Patel, Manish R; Falchook, Gerald S; Wang, Judy S; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Miah, Kowser; Mugundu, Ganesh M; Jones, Suzanne F; Spigel, David R; Hamilton, Erika P